Inflammation that lasts a long time CIDP (cerebral demyelinating polyneuropathy) is an uncommon neurological condition that results in paralysis (impairment of sensory function in limbs). The ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved patisiran infusion for the treatment of adults with polyneuropathy caused by hereditary ...

CARLSBAD, Calif., Dec. 21, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved Ionis and AstraZeneca's ...

− First and Only FDA-approved Treatment Available in the United States for this Indication – − ONPATTRO Shown to Improve Polyneuropathy Relative to Placebo, with Reversal of Neuropathy Impairment ...

The FDA has approved Amvuttra, an RNA interference therapeutic for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Amvuttra (vutrisiran, Alnylam ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted ...

LONDON--(BUSINESS WIRE)--The peripheral neuropathy treatment market is poised to grow by USD 241.99 million during 2020-2024 progressing at a CAGR of almost 3% during the forecast period. Worried ...

"Chronic Inflammatory Demyelinating Polyneuropathy Market"CIDP Companies are Takeda, Argenx, Sanofi, Janssen Research and Development, Immunovant Sciences GmbH, HanAll Pharma, Roivant Sciences, Shire, ...

StemWave acoustic wave therapy offers a non-invasive alternative to traditional peripheral neuropathy treatments, with clinical data from Mercy Family Health showing approximately 85% of patients ...

TEGSEDI is first antisense oligonucleotide medicine available to patients in Portugal for at-home subcutaneous injection BOSTON, June 1, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a ...